Ligand Pharmaceuticals (LGND) Income towards Parent Company (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Income towards Parent Company of -$13.3 million in Q1 2026, down 129.8% quarter-over-quarter from $44.8 million in Q4 2025, and up 68.56% year-over-year from -$7.9 million in Q1 2025.
Ligand Pharmaceuticals' Income towards Parent Company history runs 16 years deep, the most recent figure standing at -$13.3 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 68.56% year-over-year to -$13.3 million; the TTM figure through Mar 2026 stood at $153.6 million (up 308.81% YoY), while the FY2025 annual figure was $124.5 million, up 3186.63% from the prior year.
- Income towards Parent Company came in at -$13.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $44.8 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $117.3 million in Q3 2025 to a low of -$42.5 million in Q1 2025.
- A 5-year average of $4.6 million and a median of -$3.0 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 136.03% in 2022 and soared 244.06% in 2025, its largest moves.
- Ligand Pharmaceuticals' Income towards Parent Company stood at -$3.0 million in 2022, then jumped by 43.58% to -$1.7 million in 2023, then plunged by 1767.15% to -$31.1 million in 2024, then jumped by 244.06% to $44.8 million in 2025, then slumped by 129.8% to -$13.3 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$13.3 million, $44.8 million, and $117.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | -2.95 Mn |
| Sep 30, 2022 | -9.24 Mn |
| Jun 30, 2022 | -13.49 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.22 Mn |
| Sep 30, 2021 | -6.62 Mn |
| Jun 30, 2021 | -5.72 Mn |
| Mar 31, 2021 | -4.66 Mn |
| Dec 31, 2020 | 17.59 Mn |
| Sep 30, 2020 | -6.70 Mn |
| Jun 30, 2020 | 22.09 Mn |
| Mar 31, 2020 | -24.13 Mn |
| Dec 31, 2019 | -7.37 Mn |
| Sep 30, 2019 | -15.25 Mn |
| Jun 30, 2019 | -14.42 Mn |
| Mar 31, 2019 | 666.34 Mn |
| Dec 31, 2018 | -42.48 Mn |
| Sep 30, 2018 | 67.36 Mn |
| Jun 30, 2018 | 73.16 Mn |
| Mar 31, 2018 | 45.28 Mn |
| Mar 31, 2016 | 731,000.00 |
| Dec 31, 2015 | 6.34 Mn |
| Sep 30, 2015 | 199.17 Mn |
| Mar 31, 2015 | 2.75 Mn |
| Dec 31, 2014 | 1.91 Mn |
| Sep 30, 2014 | 1.59 Mn |
| Jun 30, 2014 | 1.08 Mn |
| Jun 30, 2013 | 2.40 Mn |
| Mar 31, 2013 | 191,000.00 |
| Dec 31, 2012 | -1.52 Mn |
| Jun 30, 2012 | 1.80 Mn |
| Mar 31, 2012 | 1.87 Mn |
| Sep 30, 2011 | -1,000.00 |
| Mar 31, 2011 | 4,000.00 |
| Dec 31, 2010 | 2.16 Mn |
| Sep 30, 2010 | 12,000.00 |
| Jun 30, 2010 | 7,000.00 |